Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Paracelsian Inc (PRLN) -- Ignore unavailable to you. Want to Upgrade?

To: John H. Farro who wrote (4094)	1/17/1999 11:38:00 PM
From: Jonathan Schonsheck	Read Replies (1) \| Respond to of 4342

Paul, Robin & Others, As I read the 10KSB, the reference to the tablets of Andrographis Paniculata is a matter of accounting, and not business strategy. (They have value - but for the purposes of a financial statement, HOW MUCH value? Without ongoing sales to establish a "market price," use the cost of production.) I do not believe that Bernie has any plans whatsoever to sell them "at cost." Scherer HerbGel, BioFIT Certified? That's my guess. (But only a guess.) Robin - You raise some interesting points with the old press releases. (How did you get access to them?) I wonder if the compounds mentioned (other than Andro, mentioned by name) are the same ones that Roswell and SRI are testing. Finding out more about the "comparison" drugs would be good; help anyone? Perhaps the most telling conclusion: how much was squandered by the old management -- that none of these were taken to market. Jonathan